| A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis.Muscle Nerve | PMID 34890069PMC9305113 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study.Fertil Steril | PMID 34895700无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.Ann Oncol | PMID 34921960PMC9447792 | 2022-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.Lancet Respir Med | PMID 34942085无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of Zoledronic Acid in the Treatment of Nonmalignant Painful Bone Marrow Lesions: A Triple-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial (ZoMARS).J Bone Miner Res | PMID 34954857无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Iron serum levels and iron homeostasis parameters in patients with nosocomial pneumonia treated with cefiderocol: post hoc analysis of the APEKS-NP study.Eur J Clin Microbiol Infect Dis | PMID 35025025PMC8831352 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.Dig Liver Dis | PMID 35027324无 PMCID | 2022-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Does baseline quality of life predict the occurrence of complications in resectable esophageal cancer?Surg Oncol | PMID 35030410无 PMCID | 2022-Mar | 0.95 | The record describes an original Phase III randomized trial in human esophageal cancer with time-to-event endpoints, but the intervention is surgical (hybrid vs. open esophagectomy) without a drug-containing arm. It is a secondary analysis of baseline quality of life as a prognostic factor for complications and survival, not a primary drug efficacy report. | 待处理 |
| Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER).Clin Drug Investig | PMID 35041159PMC8930939 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Groups 4 Health versus cognitive-behavioural therapy for depression and loneliness in young people: randomised phase 3 non-inferiority trial with 12-month follow-up.Br J Psychiatry | PMID 35049477无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.Epilepsy Behav | PMID 35078116无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.Lancet Diabetes Endocrinol | PMID 35131037无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.Clin Ther | PMID 35131090无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized Pharmacokinetic Study of a Highly Purified Human Chorionic Gonadotropin and of a Recombinant Human Chorionic Gonadotropin Following Single Subcutaneous Administration in Healthy Women.Clin Drug Investig | PMID 35137345PMC8930902 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.Lancet Psychiatry | PMID 35151410无 PMCID | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.Lancet Oncol | PMID 35151415无 PMCID | 2022-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Weight change during the first week of life and a new method for retrospective prediction of birthweight among exclusively breastfed newborns.Acta Obstet Gynecol Scand | PMID 35156190PMC9564450 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of HSK3486 for Anesthesia/Sedation in Patients Undergoing Fiberoptic Bronchoscopy: A Multicenter, Double-Blind, Propofol-Controlled, Randomized, Phase 3 Study.CNS Drugs | PMID 35157236PMC8927014 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.Lancet Oncol | PMID 35157830无 PMCID | 2022-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Haematol | PMID 35240074无 PMCID | 2022-Mar | 0.95 | The record is a Phase III randomized trial of a drug for chemotherapy-induced thrombocytopenia in cancer patients. However, the primary efficacy endpoint is a composite proportion of responders (not requiring platelet transfusion or dose reduction/delay), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP. The report lacks Kaplan-Meier survival analysis or hazard ratios for a time-to-event outcome. Therefore, it does not meet the required criteria for inclusion in the Kaplan-Meier digitization cohort. | 待处理 |
| Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy.RMD Open | PMID 35264432PMC8915362 | 2022-Mar | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.Nature | PMID 35322232PMC8967713 | 2022-Mar | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.JCO Glob Oncol | PMID 35324270PMC9071253 | 2022-Mar | 0.95 | The study is a randomized, Phase III trial with a drug intervention (biosimilar vs. originator pegfilgrastim) in oncology, but its primary efficacy endpoint is the duration of severe neutropenia (DSN), a continuous outcome, not a time-to-event endpoint. The secondary endpoints are also incidence-based or categorical measures (e.g., incidence of severe neutropenia, febrile neutropenia, infections) and are not reported as time-to-event analyses. Therefore, it does not meet the criterion of having a primary or key secondary time-to-event efficacy endpoint. | 待处理 |
| Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer.Cancer J | PMID 35333492PMC8974185 | 2022 Mar | 0.85 | The record describes a health-related quality-of-life (HRQoL) sub-study or analysis of the Phase III RATIONALE 304 trial. The endpoints are patient-reported outcomes (mean score changes, time to deterioration in QoL), not the required primary or key secondary time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) for the main trial. Therefore, it is excluded as a 'quality_of_life' report. | 待处理 |
| Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).Mod Rheumatol | PMID 34910203无 PMCID | 2022-Feb-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of a New Sustained-release Pregabalin Formulation Compared With Immediate-release Pregabalin in Patients With Peripheral Neuropathic Pain: A Randomized Noninferiority Phase 3 Trial.Clin J Pain | PMID 35220330PMC8994039 | 2022-Feb-28 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.BMC Nephrol | PMID 35216581PMC8881824 | 2022-Feb-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.Nat Commun | PMID 35217670PMC8881608 | 2022-Feb-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).Vaccine | PMID 35039194无 PMCID | 2022-Feb-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Sublingual Dexmedetomidine vs Placebo on Acute Agitation Associated With Bipolar Disorder: A Randomized Clinical Trial.JAMA | PMID 35191924PMC8864508 | 2022-Feb-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.Lancet | PMID 35085502无 PMCID | 2022-Feb-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.Lancet | PMID 35085503无 PMCID | 2022-Feb-19 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension.Platelets | PMID 33586606无 PMCID | 2022-Feb-17 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.N Engl J Med | PMID 34891224无 PMCID | 2022-Feb-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.N Engl J Med | PMID 34904798无 PMCID | 2022-Feb-17 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study.Aesthet Surg J | PMID 34472596PMC8844979 | 2022-Feb-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).Clin Cancer Res | PMID 34810217PMC9377763 | 2022-Feb-15 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).Sci Rep | PMID 35169169PMC8847351 | 2022-Feb-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study.BMC Urol | PMID 35151280PMC8840549 | 2022-Feb-12 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.Blood | PMID 34289038PMC8832474 | 2022-Feb-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.J Clin Oncol | PMID 34890214PMC8824393 | 2022-Feb-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).J Clin Oncol | PMID 34905388无 PMCID | 2022-Feb-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.N Engl J Med | PMID 34910859PMC8693692 | 2022-Feb-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.N Engl J Med | PMID 34914868PMC8693688 | 2022-Feb-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.Eur Heart J | PMID 35023547PMC8830527 | 2022-Feb-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Survival with Cemiplimab in Recurrent Cervical Cancer.N Engl J Med | PMID 35139273无 PMCID | 2022-Feb-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients.J Headache Pain | PMID 35139816PMC8903536 | 2022-Feb-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.Circulation | PMID 34775784PMC8812430 | 2022-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Referral decisions based on a pre-hospital HEART score in suspected non-ST-elevation acute coronary syndrome: final results of the FamouS Triage study.Eur Heart J Acute Cardiovasc Care | PMID 34849660PMC8826840 | 2022-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.JAMA | PMID 35133415PMC8826179 | 2022-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |